Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late-stage program in a high-need, specialized area of neuroscience expands Teva’s innovative medicines pipeline, aligns with commercial strengths and supports both near- and long-term growth. Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up to an additional $200 million in commercial milestone payments, as well as net sales-based royalties, subject to regulatory approval PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (“Emalex”) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 data of ecopipam in children with Tourette syndrome Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late-stage program in a high-need, specialized area of ... [9696 chars]